CSPC Pharmaceutical Group Limited: Lymphoma trials

The registry lists 11 Lymphoma studies with CSPC Pharmaceutical Group Limited as lead sponsor. 2 are open to participants now and 0 have results posted.

Phase 1 5Phase 2 4Phase 4 1No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of JMT601 in Participants With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin LymphomaRecruitingNCT06725524Phase 1
• Mitoxantrone Hydrochloride Liposome Injection in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)RecruitingNCT05875428Phase 2
• Clinical Pharmacokinetics of Mitoxantrone Hydrochloride Liposome Injection in Recurrent/Refractory Lymphoma SubjectsCompletedNCT05173545Phase 1
• A Safety and Efficacy Study of Duvelisib in Relapsed/Refractory Follicular LymphomaStatus unknownNCT04707079Phase 2
• Evaluate the Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia After Chemotherapy in Patients With Non-Hodgkin's LymphomaStatus unknownNCT04497688Not applicable
• Evaluation of the Application of PEGylated Recombinant Human Granulocyte Stimulating Factor Injection (PEG-rhG-CSF) in Chemotherapy of Elderly Lymphoma PatientsStatus unknownNCT03870412Not applicable
• A Study of Liposome-entrapped Mitoxantrone Hydrochloride Injection in Relapsed/Refractory Peripheral T-cell Lymphoma and NK/T-cell LymphomaStatus unknownNCT03776279Phase 2
• A Study of Mitoxantrone Hydrochloride Liposome InfusionStatus unknownNCT02856685Phase 1/2
• PEG-rhG-CSF in Patients With Lymphoma Receiving ChemotherapyCompletedNCT02805218Phase 4
• Safety and Efficacy Study of CNOP Chemotherapy in Diffuse Large B Cell LymphomaWithdrawnNCT02595242Phase 1
• Phase I Study of Mitoxantrone Hydrochloride Liposome InjectionStatus unknownNCT02131688Phase 1